First results of DNA editing to reduce LDL are promising.

Published Date: 25 Nov 2023

Patients with familial hypercholesterolemia show reductions in LDL and PCSK9 protein in the first-in-human HEART-1 trial of in vivo DNA editing, known as VERVE-101.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot